Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.

Helena EdlundNúria Buil-BrunaKarthick VishwanathanHelen WeiRakesh RamanMiné de KockZhongqing HeHuan LiuMarshall BaekJoseph WarePriti PatelHelen TomkinsonShringi Sharma

Published in: British journal of clinical pharmacology (2021)

No clinically meaningful correlations between acalabrutinib PK exposure and efficacy and safety outcomes were observed. These data support the fixed acalabrutinib dose of 100 mg twice daily in the treatment of patients with B-cell malignancies.

Keyphrases

physical activity
electronic health record
big data
metabolic syndrome
machine learning
adipose tissue
data analysis
replacement therapy